Sulpice Laurent, Farges Olivier, Goutte Nathalie, Bendersky Noelle, Dokmak Safi, Sauvanet Alain, Delpero Jean Robert
*Department of HPB and Digestive Surgery, CHU Rennes Université de Rennes 1, Rennes, France †Department of Medical Informatics, Hôpital Beaujon, Clichy, France ‡Department of HPB and Pancreatic Surgery, Hôpital Beaujon, Clichy, Assistance Publique Hôpitaux de Parisd, Université Paris 7, Clichy, France §Department of Oncological Surgery, Institut Paoli Calmettes, Marseille, France.
Ann Surg. 2015 Nov;262(5):868-73; discussion 873-4. doi: 10.1097/SLA.0000000000001479.
The aim of this study is to compare at a national level, the early and long-term outcome of distal pancreatectomy (DP) performed by laparoscopy (LapDP) or open surgery (OpenDP) for pancreatic ductal adenocarcinoma (PDAC).
LapDP is feasible and safe for benign conditions but its use for PDAC is controversial.
French healthcare databases were screened to identify all patients who had undergone LapDP or OpenDP for PDAC between 2007 and 2012. Endpoints were (i) 90-day mortality, (ii) morbidity, (iii) transfusion rate, (iv) length of hospital stay (LOS), and (v) long-term survival. Logistic regression and adjusted Cox models were used to compare LapDP and OpenDP with regard to these outcomes. Confounders included (i) patients' characteristics; (ii) associated surgical procedures; and (iii) characteristics of the hospital. Performance of the resulting models was determined by the area under the receiver operating characteristic (ROC) curve.
Over the 6-year period, there were 2753 operations for PDAC: 2406 OpenDP and 347 LapDP (12.6%). The overall 90-day mortality rate was 5.2%; median LOS was 15 days, and median survival was 38 months. LapDP was not correlated with 90-day mortality but was associated with reduced pleuropulmonary morbidity (odds ratio (OR) 0.73, P = 0.028), blood transfusion (OR 0.44, P = 0.001), and LOS (P = 0.042), and was associated with increased survival (P = 0.0007).
LapDP has not been adopted widely for PDAC. The early and long-term results of LapDP as currently practiced are as good as those of OpenDP. The next step in the evaluation of LapDP should be a randomized controlled trial (RCT), but such a trial is likely to suffer from insufficient recruitment.
本研究旨在在全国范围内比较腹腔镜下远端胰腺切除术(LapDP)与开放手术(OpenDP)治疗胰腺导管腺癌(PDAC)的早期和长期疗效。
LapDP对良性疾病可行且安全,但其用于PDAC存在争议。
对法国医疗保健数据库进行筛选,以确定2007年至2012年间所有接受LapDP或OpenDP治疗PDAC的患者。观察终点为:(i)90天死亡率;(ii)发病率;(iii)输血率;(iv)住院时间(LOS);(v)长期生存率。采用逻辑回归和校正Cox模型比较LapDP和OpenDP在这些结局方面的差异。混杂因素包括:(i)患者特征;(ii)相关手术操作;(iii)医院特征。通过受试者操作特征(ROC)曲线下面积确定所得模型的性能。
在这6年期间,共进行了2753例PDAC手术:2406例OpenDP和347例LapDP(12.6%)。总体90天死亡率为5.2%;中位LOS为15天,中位生存期为38个月。LapDP与90天死亡率无关,但与胸膜肺部发病率降低(优势比(OR)0.73,P = 0.028)、输血(OR 0.44,P = 0.001)和LOS降低(P = 0.042)相关,且与生存率提高相关(P = 0.0007)。
LapDP尚未广泛应用于PDAC。目前实施的LapDP的早期和长期结果与OpenDP一样好。LapDP评估的下一步应该是随机对照试验(RCT),但这样的试验可能会因招募不足而受到影响。